PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates.

ABSTRACT:

Purpose

Most patients with prostate cancer treated with androgen receptor (AR) signaling inhibitors develop therapeutic resistance due to restoration of AR functionality. Thus, there is a critical need for novel treatment approaches. Here we investigate the theranostic potential of hu5A10, a humanized mAb specifically targeting free PSA (KLK3).

Experimental design

LNCaP-AR (LNCaP with overexpression of wildtype AR) xenografts (NSG mice) and KLK3_Hi-Myc transgenic mice were imaged with ⁸⁹Zr- or treated with ⁹⁰Y- or ²²⁵Ac-labeled hu5A10; biodistribution and subcellular localization were analyzed by gamma counting, PET, autoradiography, and microscopy. Therapeutic efficacy of [²²⁵Ac]hu5A10 and [⁹⁰Y]hu5A

SUBMITTER: Veach DR 

PROVIDER: S-EPMC8278668 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature